Why consent in ketamine therapy carries more weight than in most procedures
Most medical consent forms get scanned and signed in under a minute. Ketamine consent should not. The treatment sits at an unusual intersection: a controlled anesthetic, used at sub-anesthetic doses, for conditions it is not formally approved to treat, in an outpatient setting where you will experience altered consciousness and then go home a few hours later. That combination is exactly why the consent document is longer, more specific, and more interesting than a routine procedure form.
The framework we follow draws from three sources. The American Medical Association's longstanding informed-consent framework defines the core obligation: the clinician must disclose the nature of the proposed intervention, its risks and benefits, reasonable alternatives, and the consequences of refusing treatment, in language a patient can understand. The 2023 AANA Ketamine Infusion Therapy Checklist from the American Association of Nurse Anesthesiology adapts that framework to ketamine specifically, calling for documentation of risks, benefits, side effects, alternative therapies, the off-label nature of the treatment for psychiatric indications, and explicit management of patient expectations. The 2024 ASKP3 Standards of Care for Ketamine Therapy from the American Society of Ketamine Physicians, Psychotherapists and Practitioners adds a parallel set of expectations, including documented vital signs and a pre-procedure evaluation alongside the consent itself.
None of that is theatre. The form exists so you can walk in clear-eyed.
Section by section: what you will see and what it actually says
Our consent form is organized roughly the way the AANA checklist is organized. We will walk you through each section at your consult, but here is the map you can read in advance.
Indications and proposed treatment. This section names the condition we are treating (for example, treatment-resistant depression, PTSD, chronic pain), the medication (ketamine), the route (intravenous infusion), and the planned series. It is the "what we are doing and why" paragraph.
Off-label status. Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and most pain indications is off-label. The form states this directly. The next section of this article explains what that phrase actually means.
Risks and side effects. Dissociation, transient blood pressure and heart rate elevation, nausea, headache, and rare urinary or psychiatric effects. We cover the specifics below.
Benefits. A realistic, condition-specific summary. Not a sales pitch.
Alternatives. Other treatments you could pursue instead, including doing nothing.
Monitoring and what we do if X happens. The form documents that vital signs are monitored continuously and that a CRNA is in the room and oversees every infusion. It also describes what happens if blood pressure rises, if you become very nauseated, or if you ask us to stop.
Photography, recording, and data sharing. Whether the clinic ever records sessions (we do not, by default), whether deidentified data may be used for quality improvement, and what HIPAA does and does not allow.
Right to refuse or stop. A standalone clause stating you can withdraw consent at any time, including mid-session.
Financial disclosure. The session fee, what is and is not included, our policy on insurance, and our cost transparency. We list $475 per session on the form and on our public materials.
Confidentiality. Who has access to your chart, when we are legally required to disclose information, and how communication with your other providers works.
The off-label disclosure: what "not FDA-approved for depression" actually means
This is the line that worries patients the most, and the one most often misunderstood. Ketamine is FDA-approved as an anesthetic; its use for depression, anxiety, PTSD, and pain is off-label. Spravato (esketamine), a related but distinct drug, is FDA-approved for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. IV racemic ketamine is not.
Off-label prescribing is legal, common, and routine across medicine. A frequently cited estimate is that roughly one in five prescriptions written in the United States is for an off-label use, and the proportion is higher in psychiatry and pediatrics. The FDA regulates which claims a manufacturer can make in marketing; it does not dictate clinical practice. Once a drug is approved, physicians and qualified practitioners can use it for indications supported by clinical judgment and the medical evidence.
What the disclosure means in practice is that you are entitled to know the regulatory status before you decide. It is not a warning that the treatment is unproven or fringe. The body of randomized trials supporting ketamine in depression and several pain conditions is substantial, and that is exactly why the AANA, ASKP3, and most professional bodies have published standards of care for it. We have a longer explanation in our piece on the FDA and ketamine if you want the regulatory detail.
The risks section: dissociation, blood pressure, nausea, urinary, psychiatric, addiction
The risks section is where the form gets specific. Research suggests the risk profile of supervised, single-session IV ketamine at sub-anesthetic doses is well characterized, and the consent reflects that.
- Dissociation. Almost everyone notices a shift in perception during the infusion. Some find it pleasant and curious; others find it disorienting. It resolves within minutes of the drip ending. The form names it as an expected effect, not a complication.
- Blood pressure and heart rate elevation. Ketamine transiently raises both. We monitor continuously and have medications on hand to bring numbers down if needed. This is one of the main reasons a CRNA-led setting matters.
- Nausea. Common, mild, and usually preventable with pre-medication and slow induction.
- Lower urinary tract symptoms. Documented mainly in chronic high-dose recreational ketamine use. Rare at therapeutic infusion frequencies, but the form names it because the FDA's 2023 Drug Safety Communication on compounded ketamine specifically called it out.
- Psychiatric worsening. Uncommon, but the form discloses that some patients experience increased anxiety, agitation, or rare emergence of psychotic symptoms. This is one reason we screen carefully and decline some patients — a process we describe in when we decline ketamine.
- Addiction and misuse. Ketamine is a Schedule III controlled substance with documented abuse potential outside clinical settings. In supervised infusion therapy at therapeutic doses, the risk is low but not zero, and the form names it.
For the broader safety context, our safety overview walks through monitoring, screening, and adverse event rates in more depth.
Benefits, alternatives, and what we do if you ask us to stop
The benefits paragraph is intentionally measured. Studies indicate that IV ketamine produces rapid antidepressant effects in a meaningful subset of patients with treatment-resistant depression, and evidence supports its use in several chronic pain conditions. The form does not promise outcomes. It frames benefit as possible and partial, not assured.
The alternatives section names the realistic options: continued medication management with your prescribing provider, psychotherapy alone, transcranial magnetic stimulation, electroconvulsive therapy, Spravato, and doing nothing. Each carries its own risk-benefit profile. We have written comparisons of ketamine versus Spravato, ketamine versus TMS, and ketamine versus ECT if you want to weigh them side by side before signing anything.
The "right to stop" clause is the one we want patients to underline. Consent is ongoing. You can withdraw it before the IV is placed, after the IV is placed but before we start the infusion, during the infusion itself, or between sessions in a series. If you ask us to stop, we stop. There is no penalty, no argument, and no pressure to keep going. The infusion is reversible by simply ending it; the medication clears quickly.
Photography, recording, data sharing, and confidentiality
Patients often ask whether sessions are recorded. They are not, by default. Some clinics use recording for safety review or research; ours does not, and the form states that explicitly. If anything ever changed, we would ask separately and in writing — never by burying it in a general consent.
Data sharing is limited to what HIPAA permits and what you authorize. Deidentified, aggregated outcomes data may be used internally to track our results and improve protocols. Identifiable information is not shared with outside parties without your written authorization, except where law requires (for example, mandated reporting of imminent harm to self or others). Communication with your other providers — your PCP, your therapist, your prescriber — happens only when you sign the specific release, and you can revoke that release at any time.
The financial disclosure section restates the per-session fee, our consultation fee structure, and the fact that insurance generally does not cover IV ketamine for psychiatric or pain use. We are not coy about this. The form, the website, and the consult conversation all carry the same number.
Bringing the form home before signing — yes, that is allowed
You do not have to sign in the room. We email the consent forms ahead of your initial consultation precisely so you can read them at home, mark them up, and bring questions. If something is unclear or feels off, that is a signal to slow down, not push through. The AMA's informed-consent framework explicitly contemplates time for the patient to consider the decision; the AANA checklist treats the conversation as the heart of consent and the signature as the documentation of it.
Practically, that means you can: read the form before your consult, take notes, run it past your prescribing provider or therapist, and only sign once your questions are answered. We will not pressure a same-day signature. If you are someone who likes to read everything twice, we encourage that, and our guide to your first infusion covers what comes after the form is signed and you arrive for treatment day.
For more on how the clinic operates around these documents — the team, the room, the monitoring — see how it works and about.